Published in Clinical Oncology Week, November 21st, 2005
The purpose of the trial is to assess the safety and tolerability and study the pharmacokinetics of Tarvacin anticancer in patients with advanced solid tumor malignancies who have failed to respond to available treatments.
Tarvacin anticancer is a monoclonal antibody that binds specifically to phospholipids, a basic component of the cell structure that is exposed only on the surface of tumor blood vessel cells and is not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.